National Cancer Institute Launches Multi-Cancer Blood Test Trial at Eight Centers Nationwide
核心洞察
The National Cancer Institute has funded the Vanguard Study on Multi-Cancer Detection, evaluating two blood tests that can screen for 10 different cancer types simultaneously.
The study will enroll up to 24,000 participants across eight cancer centers to inform the design of a larger 225,000-person trial as part of the Cancer Moonshot initiative.
The blood tests detect cancer cell fragments in the bloodstream and could enable early detection before patients become symptomatic, when cancers are more treatable.
The National Cancer Institute has launched a groundbreaking clinical trial to evaluate blood tests capable of detecting 10 different types of cancer simultaneously, potentially revolutionizing early cancer screening. The Vanguard Study on Multi-Cancer Detection is now underway at eight cancer centers nationwide, including the CU Anschutz Cancer Center (搜索), as part of the Biden-Harris administration's Cancer Moonshot initiative.
Multi-Cancer Detection Technology
The study is evaluating two blood tests that screen for pancreatic, stomach, ovarian, bladder, breast, colorectal, liver, lung, esophageal and prostate cancers. According to principal investigator Dr. Linda Cook at CU Anschutz, the tests work by detecting cancer cells that break up into fragments and enter the bloodstream.
"The idea with this is that it's just a simple blood test and you can, you know, detect many of them at the same time," Cook explained. The technology represents a significant advancement over current screening methods, which typically focus on individual cancer types and often require more invasive procedures.
Clinical Trial Design and Objectives
The Vanguard Study will enroll up to 24,000 people to inform the design of a much larger trial involving approximately 225,000 participants. The larger trial will evaluate whether the benefits of using multi-cancer detection (MCD) tests to screen for cancer outweigh the harms, and whether they can detect cancer early in a way that reduces deaths.
Cook emphasized the potential for early intervention: "That's exactly what we want to do — we want to move this timeline back so we catch it when it's early and treatable." The blood tests could become part of routine panels performed at doctor's offices, enabling detection before patients develop symptoms.
Comprehensive Evaluation Parameters
The study will measure multiple parameters including accuracy, cost-effectiveness, survival rates, and patients' anxiety levels around screening. Researchers aim to reach diverse populations receiving care in various healthcare settings, including rural areas, ensuring the findings are broadly applicable across different demographic groups and healthcare environments.
Timeline and Future Implementation
Results from the Vanguard Study are not expected for several years, as the research is designed to take "a number of years" to complete. The comprehensive nature of the evaluation reflects the rigorous standards required for implementing new screening technologies that could fundamentally change cancer detection protocols.
The blood tests could eventually be integrated into routine healthcare visits, offering the possibility of detecting multiple cancers through a single, minimally invasive procedure. This approach represents a paradigm shift from current cancer screening practices, which often require separate tests for different cancer types and may miss early-stage diseases that lack obvious symptoms.